Dermatology Times: May 11, 2025

1234567891011121314
Across
  1. 3. Receptor agonist class showing promise in managing psoriasis
  2. 6. Skin cancer spotlighted during May awareness initiatives
  3. 7. US agency launching AI integration across all centers by mid 2025
  4. 9. Key factor in aesthetic dermatology supported by cultural competency
  5. 11. Biologic target with potential to reshape AD treatment strategy
  6. 12. Topical JAK inhibitor improving HRQoL in chronic hand eczema
  7. 13. Media brand acquired by Dermatology Times' parent company to expand beauty coverage
  8. 14. Off-label IL-17A inhibitor effective for hidradenitis suppurativa after adalimumab failure
Down
  1. 1. Selective ITK inhibitor showing rapid efficacy in phase 1 atopic dermatitis trial
  2. 2. JAK inhibitor with cardiovascular risk reduction benefits in AD
  3. 4. Ongoing challenge in dermatology patient treatment plans
  4. 5. PDE4 inhibitor showing dual-site efficacy in scalp and body psoriasis
  5. 8. JAK1 inhibitor with age-linked safety differences in AD treatment
  6. 10. (Abbreviation) Dermatology society collaborating with AAD for inclusive clinical visuals